Novavax (NVAX) › Analysis

Novavax (NVAX) stock analysis, November 13, 2026: bearish outlook amid weakening momentum

Published November 13, 2026 · NVAX chart, levels and live analysis

Novavax, Inc. (NVAX) fell sharply to $8.49 on November 13, a 3.1% drop that left the price well below its 40‑week average and the swing‑zone resistance at $8.97. The daily trend now mirrors a broader weekly downtrend, and the stock is lagging both the S&P 500 and the healthcare sector (XLV) by double‑digit percentages over the past 50 days. The balance of evidence points to a high‑conviction bearish reading for the next two to six weeks, with the downside math targeting the 52‑week low at $6.22.

Why it matters

The most recent catalyst was the Q3 2026 earnings release on November 5, where Novavax reported $68.3 million in revenue, a modest 3% decline year‑over‑year, and a narrowed net loss of $31 million versus $202 million a year earlier. Management highlighted progress on the Sanofi partnership and cost controls, raising the full‑year revenue framework to $400 million at the midpoint. The earnings beat on product sales and the guidance hike were quickly priced in, as the stock rallied to $11.48 on October 16 before sliding back to today’s level.

Even with the earnings beat, the stock’s 5‑day performance was –21.2%, while the S&P 500 rose 1.9% and XLV gained 1.8% over the same period. The stock‑minus‑sector delta of –23% shows that the move was driven almost entirely by NVAX‑specific weakness rather than broader market or sector dynamics. Volume was 64.7% below its 20‑day average, indicating limited buying interest despite the earnings surprise.

Analyst consensus remains a “Buy” with a mean price target of $14.11, but that target is 39.8% above the current price, reflecting a wide valuation gap. The low end of the analyst range sits at $7.0, just below today’s price, while the high end stretches to $25.0, underscoring the divergence between market expectations and analyst optimism.

Debate in the media is mixed. Investing.com reiterated a sell rating, noting a 10.5% intraday drop to $11.48 on October 16 and a short‑interest estimate of roughly 28% of float, implying bearish pressure from short sellers. Conversely, no strong bullish arguments appeared in the recent news flow; the Jefferies London Healthcare Conference participation announced on November 11 is a routine investor‑relations event and did not move the price.

What the evidence says

On the long‑term view, the price remains below its 40‑week average, confirming that the up‑trend that justified the previous bullish stance has been broken. The weekly trend is now down, and the stock is holding below the swing‑zone resistance at $8.97, where sellers have historically stepped in on rallies. This shift weakens the longer‑term thesis that the stock could sustain higher levels.

For the next two to six weeks, the balance of evidence leans negative with high conviction. The daily trend aligns with the weekly downtrend, the stock is lagging the market by –17.8% over 50 days and the healthcare sector by –25.2% over the same horizon, and the breakout math points to a downside target of $6.22 with a reward‑to‑risk of 2.4. The strongest case against this reading would be a rapid rally above the 200‑day SMA at $9.3337, which would invalidate the current downside bias, but such a move would require a decisive weekly close above that level—something the price action has not yet shown.

Levels that matter

The structure holds the price below $8.97, the swing‑zone resistance that has acted as a ceiling on recent rallies. A weekly close above the 200‑day SMA at $9.3337 would signal the end of the current downtrend, as that level is the point where the weekly trend could flip.

The breakout math is based on a daily close below $8.31, the lower swing‑zone support. The stop is set at $9.18, derived from $8.97 plus a quarter of the 14‑day ATR ($0.82). The primary target is the 52‑week low at $6.22, offering a reward‑to‑risk of 2.4. Because the math does not achieve a 3‑to‑1 ratio, a price move to roughly $5.5 would be needed to improve the risk‑reward profile to that level.

What would change the picture

A weekly close above the 200‑day SMA at $9.3337 would reset the weekly trend and could shift the bias toward the upside. Any material update to the Sanofi partnership, such as a new licensing deal or accelerated cash‑flow timeline, would also alter the narrative.

What to watch

Get a message when the NVAX picture changes — the agent team watches the levels and the news for you.Create a free account

More NVAX analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.